

JUN-03-2008 TUE 03:35 PM AMGEN

FAX NO. 8054998011

P. 01

RECEIVED
CENTRAL FAX CENTER

AMGEN INC.

JUN 03 2008

One Amgen Center Drive
Thousand Oaks, CA 91320
(805) 499-5725

Telecopier Number: (805) 499-8011 or (805) 447-1090

DATE: June 3, 2008

TO: USPTO - Fax # 571-273-8300
Examiner: Teresa D. Wessendorf
Group Art Unit: 1639

FROM: Timothy J. Gaul
Phone: (805) 447-2688

RE: U.S. Patent Appln. Ser. No. 10/645,784
Filed: August 18, 2003
Entitled: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS
Inventors: Felge, et al.
Group Art Unit: 1639
Our Ref: A-527E

Enclosed are the following:

1. 1 page Amendment Transmittal
2. 4 pages Amendment and Response

Thank you,
Timothy J. Gaul
Reg. # 33,111

There are a total of 6 pages being transmitted. This transmission may contain confidential and/or privileged information intended solely for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If all pages are not received or if you have received this facsimile in error, please notify us immediately by calling (805) 447-6855.


JUN-03-2008 TUE 03:35 PM AMGEN

RECEIVED FAX NO. 8054998011
CENTRAL FAX CENTER

P. 02

JUN 03 2008

PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL				Attorney's Docket No: A-527E		
Serial No.	Filing Date	Examiner	Group Art Unit			
10/645,784	August 18, 2003	Teresa D. Wessendorf	1639			
In Re Application of Feige et al. For MODIFIED PEPTIDES AS THERAPEUTIC AGENTS						
TO THE COMMISSIONER FOR PATENTS:						
<input type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):						
<input type="checkbox"/> One month of original due date (\$120.00) <input type="checkbox"/> Two months of original due date (\$460.00) <input type="checkbox"/> Three months of original due date (\$1,050.00) <input type="checkbox"/> Four months of original due date (\$1,640.00) <input type="checkbox"/> Five months of original due date (\$2,230.00)						
<input type="checkbox"/> A response in connection with the matter for which this extension is requested: <input type="checkbox"/> is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuing application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.						
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required. <input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
CLAIMS AS AMENDED						
(1)	(2) Claims remaining After amendment	(3)	(4) Highest number Previously paid for	(5) No. of Extra claims present	(6)	(7) Additional Fee
Total Claims	Minus	=	0	x \$50	=	\$ 0.00
Indep. Claims	Minus	=	0	x \$210	=	\$ 0.00
<input type="checkbox"/> First Appearance of a multiple dependent claim						+ \$370 = \$ 0.00
Total Additional Fee for this Amendment						\$ 0.00
<small>* If the entry in column 2 is less than the entry in column 4, write "0" in column 5. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.</small>						
<input type="checkbox"/> The following other fees are incurred by the accompanying papers. <input type="checkbox"/> Other: _____ <input type="checkbox"/> Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ _____. A duplicate copy of this petition is attached. <input type="checkbox"/> If an additional extension of time is required, please consider this a request therefore. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees, which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.						
<u>Please Send Future Correspondence To:</u> 21069 U.S. Patent Operations/TJG M/S 28-2-C AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799, USA						
 Timothy J. Gaul Attorney/Agent for Applicant(s) Registration No.: 33,111 Phone: (805) 447-2688 Date: June 3, 2008						

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

June 3, 2007
Date

Suzanne Nessary

JUN-03-2008 TUE 03:36 PM AMGEN

RECEIVED
CENTRAL FAX CENTER FAX NO. 8054998011

P. 03

JUN 03 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige et al.

Serial No.: 10/645,784

Group Art Unit No.: 1639

Filed: August 18, 2003

Examiner: Teresa D. Wessendorf

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

AMENDMENT AND RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to telephone interviews with the Examiner on May 30th and June 2nd, 2008 regarding the above-identified patent application, the Applicants respectfully submit the claims appearing below.

Amendments to the Claims begin on page 2 of this paper


Remarks/arguments begin on page 4 of this paper.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

June 3, 2008

Date


Suzanne Nessary